Skip to Content

Hemlibra FDA Approval History

FDA Approved: Yes (First approved November 16, 2017)
Brand name: Hemlibra
Generic name: emicizumab-kxwh
Dosage form: Injection
Company: Genentech, Inc.
Treatment for: Hemophilia A with Inhibitors, Hemophilia A

Hemlibra (emicizumab-kxwh) is a bispecific factor IXa- and factor X-directed antibody indicated to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.

Development Timeline for Hemlibra

DateArticle
Oct  4, 2018Approval FDA Approves Genentech’s Hemlibra (emicizumab-kxwh) for Hemophilia A Without Factor VIII Inhibitors
Apr 16, 2018FDA Grants Breakthrough Therapy Designation For Genentech’s Hemlibra (emicizumab-kxwh) in Hemophilia A Without Inhibitors
Nov 16, 2017Approval FDA Approves Hemlibra (emicizumab-kxwh) for Hemophilia A with Inhibitors

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.